Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Cannabis Extracts for Osteoarthritic Pain (COPE)
NCT06878417Recruiting
- Sponsor
- University Health Network
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in osteoarthritis (OA) comparing CBD (Cannabidiol), THC (Δ9-tetrahydrocannabinol) and Placebo (3 arms). Primary endpoints: Feasibility outcome: pertaining to the enrollment rate at 1 year, Feasibility outcome: pertaining to the Protocol adherence at 8 weeks and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
cannabidioldronabinol
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06878417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878417.